

QUESTION 8

Matthew Malcolm Andrew Waite, Louise Langmead, and Ruth M Ayling Faecal calprotectin is not necessarily required as a screen for significant bowel disease in primary care

Annals of Clinical Biochemistry 2022 59:3, 171-177

(a) You would like to propose removing faecal calprotectin measurement for the investigation of bowel disease in primary care. Write an executive summary, based on this paper, to be discussed at your hospital board meeting, outlining the advantages and risks associated with this. (10 marks)

(b) As discussed in the paper, outline the current use of:

(i) Faecal haemoglobin (2)

(ii) Faecal calprotectin (2)

(c) Outline the consequences of using the NICE recommended cut-off for faecal calprotectin, given that faecal calprotectin assays are known not to correlate well. (4)

(d) Which patient group would faecal calprotectin continue to be measured in, and how would the results be used? (2)